Long‐term production of pre‐existing alloantibodies to E and c after allogenic BMT in a patient with aplastic anemia resulting in delayed hemolytic anemia

Izumi, Noriko; Fuse, Ichiro; Furukawa, Tatsuo; Uesugi, Yoshihiko; Tsuchiyama, Junjiro; Toba, Ken; Togashi, Kazue; Yamada, Kazutaka; Ohtake, Sachiko; Saitoh, Y; Yanagisawa, Naoe; Aizawa, Yoshifusa

doi:10.1046/j.1537-2995.2003.00303.x

Cited by 21 publications

(19 citation statements)

References 24 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, long-term follow-up is needed since immunohematological complications may develop even many years after BMT. 32 Immunohematological follow-up is also important for monitoring marrow engraftment and disease status. In fact, following an ABO-matched BMT, it is possible to identify a chimeric antigen of Rh or other red cell group systems whose appearance/disappearance in the post transplant period gives the opportunity to evaluate the marrow engraftment.…”

Section: Discussionmentioning

confidence: 99%

“…Rh system Anti-D, -C, -c, -E Delayed hemolytic anemia, 13,21,32 which may be severe after major Rh-mismatched grafts. 15 Passenger lymphocyte syndrome 7 and chronic hemolysis (in the case of persistence of mixed chimerism) 8 have also been described Kell system Anti-Kell Delayed hemolytic anemia 25,28 Kidd system Anti-JK a , -JK b Severe acute hemolytic anemia with intravascular hemolysis (passenger lymphocyte syndrome), 6,29 delayed hemolytic anemia 25 …”

Section: Mechanism Of Hemolysismentioning

confidence: 99%

See 1 more Smart Citation

Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation

Franchini

Gandini

Aprili

2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Immune-mediated hemolysis is a well-recognized occurrence which complicates the period following a bone marrow transplant (BMT). However, although many studies have investigated the hemolytic anemia following ABO-incompatible BMT, data regarding the occurrence of alloantibodies against red blood cell (RBC) antigens other than ABO in patients undergoing hematopoietic stem cell transplantation are limited. In this review, we briefly analyze the most important non-ABO red blood cell (RBC) antigen systems involved in the development of post-BMT alloimmune hemolytic anemia, paying particular attention to the pathogenic mechanisms and the clinical significance of the alloantibodies involved. Among the non-ABO RBC antigens, RhD antigen is the one most frequently implicated in the development of post-BMT alloimmune hemolytic anemia. Although less frequent than hemolysis following transplants with ABO incompatibility, non-ABO-incompatible allograft hemolysis may severely complicate the post-BMT period creating difficult clinical management issues. For this reason, we advise careful pre-transplant donor and recipient checks for the most important RBC antigen systems and close post-BMT immunohematological monitoring in those patients undergoing allogeneic hematopoietic stem cell transplant with RBC antigen incompatibility.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Mechanism Of Hemolysismentioning

confidence: 99%

Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation

Franchini

Gandini

Aprili

2004

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…9 Even when peripheral circulating B cells are solely of donor origin, hemolysis may be mediated by long-term production of antibodies by long-living recipient plasma cells, which survive the conditioning regimen, as was observed from 1-20 months after allogeneic BMT. 10 We conclude that patients with RhD-mismatch transplanted from donors with pre-existing anti-RhDalloantibodies may quickly eliminate recipient-type erythrocytes and should be carefully followed-up for…”

mentioning

confidence: 88%

Post-transplant induction of donor-type anti-RhD antibodies production shortly followed by complete hemolysis of recipient-type erythrocytes in RhD-mismatched allogeneic bone marrow recipient

Markiewicz¹,

Wojnar²,

Giebel³

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

“…When alloantibodies against RBCs are produced by the post-transplantation immune system, the antibodies may persist for several years, 68 and they may be produced by the engrafted cells of the immune system of the donor [69][70][71] or by the residual cells of the immune system of the recipient. 68,72,73 The antibodies produced may be against donor RBCs, residual recipient RBCs, or, in some cases, both. The incidence of alloantibody formation against minor RBC antigens ranges from 2.1% to 3.7% in the published literature.…”

Section: Minor Mismatchesmentioning

confidence: 99%

Transfusion Support Issues in Hematopoietic Stem Cell Transplantation

Cohn

2015

Cancer Control

View full text Add to dashboard Cite

on canvas printed with an image of myxofibrosarcoma with metastases to the artist's lung, 26" × 36". Minnesota, Minneapolis, Minnesota. Submitted March 27, 2014; accepted July 23, 2014. Address correspondence to Claudia S. Cohn, MD, PhD, D242 Mayo Memorial Building, MMC 609, 420 Delaware Street, South East, Minneapolis, MN 55455. E-mail: cscohn@umn antigen (HLA) matching remains an important predictor of success with HSCT; however, the ABO barrier is often crossed when searching for the most appropriate HLA match between donor and patient. Crossing the ABO barrier has little or no effect on overall outcomes; however, complications can arise due to antigenic incompatibility between the transplanted cells and the patient. From the Department of Laboratory Medicine and Pathology, University of1 This review will discuss the transfusion support of patients receiving HSCT, common transfusion-related complications that health care professionals will likely encounter, and the measures required to safely deliver blood components.HSCTs can be broadly divided into related allogeneic, unrelated allogeneic, and autologous transplantation. Hematopoietic progenitor cells (HPCs) for allogeneic transplantation come from 3 sources: apheresis-derived, mobilized peripheral blood pro- Transfusion Support Issues in Hematopoietic Stem Cell Transplantation

show abstract

Long‐term production of pre‐existing alloantibodies to E and c after allogenic BMT in a patient with aplastic anemia resulting in delayed hemolytic anemia

Cited by 21 publications

References 24 publications

Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation

Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation

Post-transplant induction of donor-type anti-RhD antibodies production shortly followed by complete hemolysis of recipient-type erythrocytes in RhD-mismatched allogeneic bone marrow recipient

Transfusion Support Issues in Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About